- New report highlights importance of expanding pharmacists' role in Canada
- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Shoppers Drug Mart unveils arthritis screening program in Canada
- FDA approves easy-to-use injectable methotrexate for RA, psoriasis, juvenile arthritis
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
EAST BRUNSWICK, N.J. Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors at the end of this month, Savient said.
The company announced that it would begin shipping Krystexxa (pegloticase) on Nov. 30, and it would become available for prescription on Dec. 1.
“The commercial availability of Krystexxa marks another significant milestone for both patients and the company, as it is the first FDA-approved therapy that addresses a significant unmet medical need in the treatment of chronic gout in adult patients refractory to conventional therapy,” Savient president Paul Hamelin said in a statement.